Niagen Bioscience (NASDAQ:NAGE) Posts Quarterly Earnings Results, Meets Estimates

Niagen Bioscience (NASDAQ:NAGE) released its quarterly earnings results on Wednesday. The company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01), FiscalAI reports. The business had revenue of $27.19 million during the quarter. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%.

Niagen Bioscience Stock Up 6.8%

Shares of Niagen Bioscience stock traded up $0.16 on Wednesday, hitting $2.52. 673,807 shares of the company’s stock traded hands, compared to its average volume of 838,320. The stock has a market cap of $200.69 million, a P/E ratio of 14.00 and a beta of 2.12. The firm’s 50-day moving average is $2.81 and its 200 day moving average is $3.87. Niagen Bioscience has a 52-week low of $2.31 and a 52-week high of $7.95.

Analysts Set New Price Targets

A number of equities analysts have commented on NAGE shares. Roth Capital reiterated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday, August 5th. Canaccord Genuity Group decreased their price objective on shares of Niagen Bioscience from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, October 30th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research note on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $10.00.

Institutional Trading of Niagen Bioscience

Hedge funds have recently made changes to their positions in the stock. Gamco Investors INC. ET AL raised its holdings in Niagen Bioscience by 2.5% in the first quarter. Gamco Investors INC. ET AL now owns 165,000 shares of the company’s stock valued at $728,000 after acquiring an additional 4,000 shares in the last quarter. Teton Advisors LLC boosted its stake in Niagen Bioscience by 20.0% during the 1st quarter. Teton Advisors LLC now owns 30,000 shares of the company’s stock valued at $132,000 after acquiring an additional 5,000 shares during the last quarter. Gabelli Funds LLC boosted its stake in Niagen Bioscience by 5.2% during the 1st quarter. Gabelli Funds LLC now owns 214,685 shares of the company’s stock valued at $947,000 after acquiring an additional 10,685 shares during the last quarter. Kestra Advisory Services LLC boosted its stake in Niagen Bioscience by 81.5% during the 3rd quarter. Kestra Advisory Services LLC now owns 24,500 shares of the company’s stock valued at $72,000 after acquiring an additional 11,000 shares during the last quarter. Finally, Stoneridge Investment Partners LLC acquired a new position in Niagen Bioscience during the 2nd quarter worth $49,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.